• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

March 20, 2013

View Archived Issues

Safinamide Hits Endpoints in Two Parkinson's Phase III Trials

Newron Pharmaceuticals SpA and its partner, Zambon SpA, remain on track to file for approval for safinamide as add-on therapy in Parkinson's disease in the fourth quarter, following the release of pivotal Phase III data at the annual meeting of the American Academy of Neurology in San Diego this week. Read More

Other Omontys Shoe Drops as Affymax Cuts Work Force Deep

Affymax Inc.'s stock-ravaging decision to let go 75 percent of its employees after the voluntary recall of Omontys (peginesatide) puts the spotlight ever more strongly on safety with regard to erythropoiesis-stimulating agents, and could bode well for Amgen Inc.'s anemia franchise. Read More

Committee to Scrutinize Titan's Implantable Buprenorphine

Briefing documents released ahead of a scheduled meeting March 21 of the Psychopharmacologic Drugs Advisory Committee sent shares of Titan Pharmaceuticals Inc. plummeting 41.7 percent Tuesday. Read More

GW Pharma Files for $50M IPO with Sativex in Phase III

The cannabis-based drug specialist GW Pharma plc has filed for a listing on Nasdaq, with the ambition of raising up to $50 million to turbo-charge development of its preclinical pipeline and expand manufacturing capacity in anticipation of the U.S. launch of its lead product Sativex. Read More

InSite Shares Gain on BromSite Phase III Data

Investors took notice as InSite Vision Inc. reported positive top-line findings from its first Phase III trial of BromSite (ISV-303) for the reduction of inflammation and pain following cataract surgery. The company said BromSite, which combines a low dose (0.075 percent) of the nonsteroidal anti-inflammatory (NSAID) bromfenac with InSite's DuraSite drug delivery technology, achieved statistically significant superiority compared to vehicle. Read More

High Court Mulls Drugmakers' Liability in Preemption Case

A lot of eyes were on the Supreme Court Tuesday as it considered arguments in Mutual Pharmaceutical Co. v. Bartlett, a case that could further define generic drug preemption or pave the way for more liability for all drugmakers. Read More

Stock Movers

Read More

NPS Reclaims Rights to 2 Drugs From Takeda in $50M Stock Deal

NPS Pharmaceuticals Inc. regained full worldwide rights to teduglutide (Gattex) and recombinant human parathyroid hormone 1-84 (PTH 1-84/Preotact) from Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, in exchange for common stock valued at $50 million, plus a milestone payment of $30 million in cash or stock in the first year that net sales of both products exceed $750 million. Read More

Other News To Note

• Stellar Biotechnologies Inc., of Port Hueneme, Calif., submitted a Type IV Biologics Master File to the FDA's Center for Biologics Evaluation and Research for its subunit Keyhole Limpet Hemocyanin (KLH). Read More

Pharma: Other News To Note

• Boehringer Ingelheim Pharmaceuticals Inc., of Ridgefield, Conn., part of Boehringer Ingelheim GmbH, said a new perspective from the FDA stated the agency has not changed its recommendations regarding Pradaxa (dabigatran etexilate mesylate) capsules, following the November 2012 Mini-Sentinel evaluations. Read More

Clinic Roundup

• Impax Pharmaceuticals, of Hayward, Calif., a division of Impax Laboratories Inc., disclosed the presentation of results from its Rytary (IPX066) Phase III and open-label extension trials at the 65th Annual Meeting of the American Academy of Neurology in San Diego on March 18. Read More

Pharma: Clinic Roundup

• Boehringer Ingelheim Pharmaceuticals Inc., of Ridgefield, Conn., part of Boehringer Ingelheim GmbH, and Eli Lilly and Co., of Indianapolis, started a Phase IIIb trial to evaluate the glycemic efficacy and safety of linagliptin in patients with Type II diabetes with prevalent albuminuria. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 4, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 4, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • KT-621: a first-in-class STAT6 degrader for Th2-driven diseases

    BioWorld Science
    STAT6 plays a central role in regulating Th2-driven immune responses. Recent studies have identified gain-of-function mutations in the STAT6 gene that are...
  • Woman holding neck

    Merus combo trounces Keytruda in head-and-neck phase II

    BioWorld
    Investor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe